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(57) ABSTRACT 
Disclosed is a method of detecting a concentration of a 
biomarker in a human subject having or being at risk of 
developing Alzheimer's disease or Mild Cognitive Impair­
ment (MCI). Also disclosed is a process for detecting a 
concentration of a biomarker in a human subject having or 
being at risk of developing Alzheimer's disease or Mild 
Cognitive Impairment (MCI) comprising (a) detecting a first 
concentration of lipocalin-PDS/TTR complex in a blood 
sample or urine sample from the subject, (b) determining a 
second concentration of PDS/TTR complex in a blood 
sample or urine sample from an unaffected individual, and 
( c) comparing the first and second concentrations, wherein
a lower first concentration as compared to the second
concentration is indicative of the subject having or being at
risk of developing Alzheimer's disease.
11 Claims, 1 Drawing Sheet 
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PROCESS FOR DETECTION OF 
ALZHEIMER'S DISEASE FROM A SERUM 
SAMPLE 
2 
optionally, instructions for using the kit to detect PDS/TTR 
in a blood sample or urine sample. 
In certain embodiments, the present invention provides a 
method of isolating a lipocalin-PDS/TTR complex bio-
RELATED APPLICATION 
This application claims priority under 35 U.S.C. 119(e) to 
provisional application U.S. Ser. No. 61/572,329, filed Jul. 
14, 2011 and to provisional application U.S. Ser. No. 61/566, 
971, filed Dec. 5, 2011, which applications are incorporated 
hereby by reference. 
5 marker from blood or urine comprising: (a) contacting the 
blood or urine with a trapping binding ligand specific for 
lipocalin-PDS to form a trapped biomarker, wherein the 
trapping binding ligand specific for lipocalin-PDS is bound 
to a solid substrate; (b) contacting the trapped biomarker 
10 with a probing binding ligand that is specific for TTR to 
form a probed biomarker complex; and (c) purifying the 
probed biomarker complex. 
FIELD OF THE INVENTION In certain embodiments, the present invention provides a 
process for detecting Alzheimer's disease in a human sub-
15 ject, the process comprising obtaining a sample of blood 
from the subject, optionally preparing a sample of serum or 
plasma from the sample of blood, determining the concen­
tration of PDS/TTR in the sample of blood, and comparing 
the concentration of PDS/TTR to a reference value. 
The present invention relates to the field of detection and 
monitoring of neurodegenerative disorders, including 
Alzheimer's disease (AD) and mild cognitive impairment 
(MCI). More particularly, the present invention relates to 
proteinaceous biomarkers that can be measured in biological 
fluids, which can be used to aid in the detection of neuro- 20 
degenerative disorders, including Alzheimer's disease and 
mild cognitive impairment. 
BACKGROUND OF THE INVENTION 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1. The PDS/TTR complex was immunoprecipitated 
from representative serum specimens from normal control 
25 (NC) and probable AD (AD) subjects using rabbit anti-TTR 
and was visualized using mouse anti-PDS. There was a 
significant decrease of immunostaining for the PDS/TTR 
complex in serum from AD patients (34.8±2.5% control) 
Previous studies suggest there is diminished transport 
capacity of high molecular weight (>30 kDa) material 
through choroid plexus epithelial cells in the progression of 
AD. Further, it has been observed that A�1 _42 levels are 
significantly lower in serum compared to CSF because of 30 
deposition in senile plaques (Solfrizzi, V, D'Introno, A, 
Colacicco, A M, Capurso, C, Todarello, 0, et al. Circulating 
biomarkers of cognitive decline and dementia Clin Chim 
Acta, 2006; 364:91-112). There is an ongoing need for 
methods for detecting biomarkers associated with AS and 
MCI. 
compared to NC subjects (100±2.9%). 
FIG. 2. Reporter operator curves for PDS/TTR and A� 1_42 
in plasma from NC (N=76) and MCI (N=45) subjects. 
Improved sensitivity/specificity of the PDS/TTR complex is 
reflected by the increased area under the curve (AUC) for 
plasma PDS/TTR (AUC=84%) compared to an A UC of 45% 
SUMMARY OF THE INVENTION 
35 for plasma A� 1_42 and 50% for CSF A�. Sensitivity/speci­
ficity of the PDS/TTR complex were 70% compared to 
sensitivity/specificity values of 52% and 44% respectively 
for A� measures. 
FIGS. 3A and 38. Commossie blue stained gel (A) 
40 showing recombinant hematopoietic PDS (lane 1) and 
lipocalin PDS (lane 2) and the Western blot of a second gel 
probed using an anti-lipocalin PDS antibody (B). 
In certain embodiments, the present invention provides 
method of detecting a concentration of a biomarker in a 
human subject having or being at risk of developing 
Alzheimer's disease (AD) or Mild Cognitive Impairment 
(MCI), the method comprising: (a) detecting a first concen­
tration of lipocalin-PDS/TTR complex in a blood sample or 45 
urine sample from the subject, (b) determining a second 
concentration of PDS/TTR complex in a blood sample or 
urine sample from an unaffected individual, and (c) com­
paring the first and second concentrations, wherein a lower 
first concentration as compared to the second concentration 50 
is indicative of the subject having or being at risk of 
developing AD or MCI. 
In certain embodiments, the present invention provides a 
method of detecting a concentration of a biomarker in a 
human subject having or being at risk of developing 55 
Alzheimer's disease (AD) or Mild Cognitive Impairment 
(MCI), the method comprising: (a) detecting a concentration 
of lipocalin-PDS/TTR complex in a blood sample or urine 
sample from the subject, (b) comparing the concentration to 
a reference value, wherein a lower concentration as com- 60 
pared to the reference value is indicative of the subject 
having or being at risk of developing Alzheimer's disease or 
MCI. 
DETAILED DESCRIPTION 
Surprisingly, the inventors found that levels of the lipoca­
lin-PDS/TTR complex biomarker in a blood sample were 
lower in subjects with Alzheimer's disease than in non­
diseased controls. The art had taught away from this finding, 
in that, according to the art, levels of the biomarker in 
cerebrospinal fluid were higher in subjects with Alzheimer's 
Disease than in non-diseased controls. 
Surprisingly, the inventors found that levels of the bio­
marker in a blood sample were lower in subjects with Mild 
Cognitive Impairment than in non-diseased controls. The art 
had taught away from this finding, in that, according to the 
art levels of the biomarker in cerebrospinal fluid were higher 
in subjects with Mild Cognitive Impairment than in non­
diseased controls. 
In certain embodiments, the present invention provides a 
concentration of a biomarker in a human subject having or 
being at risk of developing Alzheimer's disease (AD) or 
Mild Cognitive Impairment (MCI), the method comprising: 
(a) detecting a first concentration of lipocalin-PDS/TTRIn certain embodiments, the present invention provides a 
kit comprising: (a) a solid substrate; (b) a trapping binding 
ligand specific for lipocalin-PDS bound to the solid sub­
strate; (c) a probing binding ligand specific for TTR; (d) 
65 complex in a blood sample or urine sample from the subject, 
(b) determining a second concentration of PDS/TTR com­
plex in a blood sample or urine sample from an unaffected
US 9,835,621 B2 
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individual, and (c) comparing the first and second concen­
trations, wherein a lower first concentration as compared to 
the second concentration is indicative of the subject having 
or being at risk of developing AD or MCI. In certain 
embodiments, the blood sample is a sample of whole blood, 
serum, plasma, or a subcomponent of blood. In certain 
embodiments, the blood sample is a serum or plasma 
sample. As used herein, the term "blood sample" includes a 
whole blood sample or a subcomponent sample ( e.g., a 
serum sample). In certain embodiments, the lipocalin-PDS/ 10 
TTR complex is a trimer consisting of one molecule of 
lipocalin-PDS and two molecules of TTR. In certain 
embodiments, the lipocalin-PDS/TTR complex binds to a 
trapping binding ligand specific for lipocalin-PDS but not to 
a binding ligand specific for hematopoietic-PDS/TTR com- 15 
plex. In certain embodiments, the binding ligand is an 
antibody. In certain embodiments, the lipocalin-PDS/TTR 
complex is a modified lipocalin-PDS/TTR complex that 
further comprises alpha and/or beta-unsaturated aldehydic 
by-products of lipid peroxidation. In certain embodiments, 20 
the lipocalin-PDS/TTR complex binds to a probing binding 
ligand specific for TTR. In certain embodiments, the probing 
ligand specific for TTR further comprises a label generating 
a detectable signal. In certain embodiments, the label com­
prises a chemical, an enzymatic, a radioactive, a fluorescent, 25 
a luminescent, a chemiluminescent and a FRET label. In 
certain embodiments, the detection of the first concentration 
of lipocalin-PDS/TTR complex is by ELISA. 
In certain embodiments, the present invention provides a 
method of detecting a concentration of a biomarker in a 30 
human subject having or being at risk of developing 
Alzheimer's disease (AD) or Mild Cognitive Impairment 
(MCI), the method comprising: (a) detecting a concentration 
of lipocalin-PDS/TTR complex in a blood sample or urine 
sample from the subject, (b) comparing the concentration to 35 
a reference value, wherein a lower concentration as com­
pared to the reference value is indicative of the subject 
having or being at risk of developing Alzheimer's disease or 
MCI. 
4 
sample of blood, determining the concentration of PDS/TTR 
in the sample of serum, and comparing the concentration of 
PDS/TTR to a reference value. In certain embodiments, 
Alzheimer's disease is detected if the concentration of 
PDS/TTR is less than the reference value. In certain embodi­
ments, the sample of blood is collected from the subject by 
phlebotomy. In certain embodiments, the sample of serum is 
prepared from the sample of blood by permitting the sample 
of blood to clot and centrifuging the sample of blood. In 
certain embodiments, the ELISA is an ELISA described in 
U.S. Pat. No. 7,851,172. In certain embodiments, the ELISA 
provides an electromagnetic signal capable of being detected 
by an optical reader. In certain embodiments, the ELISA 
provides an electrochemical signal capable of being detected 
by an electrochemical signal detection apparatus. 
A "subject" of analysis, diagnosis, or treatment is an 
animal. Such animals include mammals, such as a human. 
A "control" cell, tissue, sample, or subject is a cell, tissue, 
sample, or subject of the same type as a test cell, tissue, 
sample, or subject. The control may, for example, be exam­
ined at precisely or nearly the same time the test cell, tissue, 
sample, or subject is examined. The control may also, for 
example, be examined at a time distant from the time at 
which the test cell, tissue, sample, or subject is examined, 
and the results of the examination of the control may be 
recorded so that the recorded results may be compared with 
results obtained by examination of a test cell, tissue, sample, 
or subject. The control may also be obtained from another 
source or similar source other than the test group or a test 
subject, where the test sample is obtained from a subject 
suspected of having a disease or disorder for which the test 
is being performed. 
A "test" cell, tissue, sample, or subject is one being 
examined. 
The use of the word "detect" and its grammatical variants 
is meant to refer to measurement of the species without 
quantification, whereas use of the word "determine" or 
"measure" with their granimatical variants are meant to refer 
to measurement of the species with quantification. The terms 
In certain embodiments, the present invention provides a 
kit comprising: (a) a solid substrate; (b) a trapping binding 
ligand specific for lipocalin-PDS bound to the solid sub­
strate; (c) a probing binding ligand specific for TTR; (d) 
optionally, instructions for using the kit to detect PDS/TTR 
40 "detect" and "identify" are used interchangeably herein. 
in a blood sample or urine sample. In certain embodiments, 45 
the solid substrate is a hydrocarbon polymer, glass, metal, or 
gel. In certain embodiments, the solid substrate is a gelatin, 
latex, polystyrene, colloidal gold, or magnetic bead. In 
certain embodiments, trapping binding ligand specific for 
lipocalin-PDS but not to a binding ligand specific for 50 
hematopoietic-PDS. 
In certain embodiments, the present invention provides a 
method of isolating a lipocalin-PDS/TTR complex bio­
marker from blood or urine comprising: (a) contacting the 
blood or urine with a trapping binding ligand specific for 55 
lipocalin-PDS to form a trapped biomarker, wherein the 
trapping binding ligand specific for lipocalin-PDS is bound 
to a solid substrate; (b) contacting the trapped biomarker 
with a probing binding ligand that is specific for TTR to 
form a probed biomarker complex; and (c) purifying the 60 
probed biomarker complex. In certain embodiments, the 
present invention provides a probed biomarker complex 
isolated according to the method described above. 
In certain embodiments, the present invention provides a 
process for detecting Alzheimer's disease in a human sub- 65 
ject, the process comprising obtaining a sample of blood 
from the subject, preparing a sample of serum from the 
Detectable Markers and Labels 
According to one embodiment, the probing binding ligand 
has a label generating a detectable signal. The label includes, 
but not limited to, a chemical (e.g., biotin), an enzymatic 
( e.g., alkaline phosphatase, peroxidase, �-galactosidase and 
�-glucosidase, horseradish peroxidase), a radioactive ( e.g., 
1125 and C14), a fluorescent ( e.g., fluorescein), a luminescent,
a chemiluminescent or a FRET (fluorescence resonance 
energy transfer) label. Various labels and methods for label­
ing binding ligands are well known in the art (Harlow and 
Lane, eds., Antibodies: A Laboratory Manual (1988) Cold 
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). 
In certain embodiments, the probing binding ligand is an 
antibody that is labeled with biotin or horseradish peroxi­
dase. 
As used herein, a "detectable marker" is an atom or a 
molecule that permits the specific detection of a compound 
comprising the marker in the presence of similar compounds 
without a marker. Detectable markers include, but are not 
limited to, radioactive isotopes, antigenic determinants, 
enzymes, nucleic acids available for hybridization, chro­
mophores, fluorophores, chemiluminescent molecules, elec­
trochemically detectable molecules, and molecules that pro­
vide for altered fluorescence-polarization or altered light­
scattering. 
The detectable labels used in the assays of the present 
invention to diagnose Alzheimer's Disease, these labels are 
US 9,835,621 B2 
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attached to the binding agent that is specific for PDS or TTR, 
can be primary labels (where the label comprises an element 
that is detected directly or that produces a directly detectable 
element) or secondary labels (where the detected label binds 
6 
galactoside. Embodiments of alkaline phosphatase sub­
strates include p-nitrophenyl phosphate (pNPP), which is 
detected with a spectrophotometer; 5-bromo-4-chloro-3-in-
dolyl phosphate/nitro blue tetrazolium (BCIP/NBT) and fast 
red/napthol AS-TR phosphate, which are detected visually; 
and 4-methoxy-4-(3-phosphonopheny l)spiro [ 1,2-dioxetane-
3 ,2'-adamantane], which is detected with a luminometer. 
Embodiments of horse radish peroxidase substrates include 
2,2'azino-bis(3-ethylbenzthiazoline-6 sulfonic acid) 
to a primary label, e.g., as is common in immunological 5 
labeling). An introduction to labels, labeling procedures and 
detection of labels is found in Polak and Van Noorden 
(1997) Introduction to Immunocytochemistry, 2nd ed., 
Springer Verlag, N.Y. and in Haugland (1996) Handbook of 
Fluorescent Probes and Research Chemicals, a combined 
handbook and catalogue Published by Molecular Probes, 
Inc., Eugene, Oreg. Patents that described the use of such 
labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939, 
350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. 
10 (ABTS), 5-aminosalicylic acid (SAS), o-dianisidine, and 
o-phenylenediamine (OPD), which are detected with a spec­
trophotometer, and 3,3,5,5'-tetramethylbenzidine (TMB),
3,3' diaminobenzidine (DAB), 3-amino-9-ethylcarbazole
(AEC), and 4-chloro-1-naphthol ( 4ClN), which are detected
15 visually. Other suitable substrates are known to those skilled 
in the art. The enzyme-substrate reaction and product detec­
tion are performed according to standard procedures known 
to those skilled in the art and kits for performing enzyme 
Primary and secondary labels can include undetected 
elements as well as detected elements. Useful primary and 
secondary labels in the present invention can include spec­
tral labels such as green fluorescent protein, fluorescent dyes 
(e.g., fluorescein and derivatives such as fluorescein isoth­
iocyanate (FITC) and Oregon Green™, rhodamine and 20 
derivatives (e.g., Texas red, tetrarhodimine isothiocynate 
(TRITC), etc.), digoxigenin, biotin, phycoerythrin, AMCA, 
CyDyes™, and the like), radiolabels (e.g., 3H, 1251, 35S, 14C,
32P, 33P, etc.), enzymes (e.g., horse radish peroxidase, alka­
line phosphatase etc.), spectral calorimetric labels such as 
colloidal gold or colored glass or plastic ( e.g. polystyrene, 
polypropylene, latex, etc.) beads. The label can be coupled 
directly or indirectly to a component of the detection assay 
(e.g., the detection reagent) according to methods well 
known in the art. As indicated above, a wide variety of labels 
may be used, with the choice of label depending on sensi­
tivity required, ease of conjugation with the compound, 
stability requirements, available instrumentation, and dis­
posal provisions. 
Exemplary labels that can be used include those that use: 
immunoassays are available as described above. 
The presence of a label can be detected by inspection, or 
a detector which monitors a particular probe or probe 
combination is used to detect the detection reagent label. 
Typical detectors include spectrophotometers, phototubes 
and photodiodes, microscopes, scintillation counters, cam-
25 eras, film and the like, as well as combinations thereof. 
Examples of suitable detectors are widely available from a 
variety of commercial sources known to persons of skill. 
Commonly, an optical image of a substrate comprising 
bound labeling moieties is digitized for subsequent com-
30 puter analysis. 
The detection of the lipocalin-PDS/TTR complex can be 
carried out by various processes well known in the art. This 
detection can be carried out quantitatively or qualitatively 
according to conventional procedures, e.g., using various 
35 detectable label/substrate pairs as described in Enzyme 
Immunoassay, E. T. Maggio, ed., CRC Press, Boca Raton, 
Fla., 1980 and Harlow and Lane, eds. Antibodies: A Labo­
ratory Manual (1988) Cold Spring Harbor Laboratory Press, 
1) chemiluminescence (using horseradish peroxidase and/or
alkaline phosphatase with substrates that produce photons as 
breakdown products as described above) with kits being 
available, e.g., from Molecular Probes, Amersham, Boeh­
ringer-Mannheim, and Life Technologies/Gibco BRL; 2) 40 
color production (using both horseradish peroxidase and/or 
alkaline phosphatase with substrates that produce a colored 
precipitate (kits available from Life Technologies/Gibco 
BRL, and Boehringer-Mannheim)); 3) fluorescence using, 
e.g., an enzyme such as alkaline phosphatase, together with
the substrate AttoPhos (Amersham) or other substrates that
produce fluorescent products, 4) fluorescence (e.g., using
Cy-5 (Amersham), fluorescein, and other fluorescent tags);
Cold Spring Harbor, N.Y. 
Where the probing binding ligand (e.g., antibody) is 
labeled with alkaline phosphatase, bromochloroindolylphos­
phate (BCIP), nitro blue tetrazolium (NBT) and ECF may be 
used as a substrate for color developing reactions; in the case 
of labeled with horseradish peroxidase, chloronaphtol, 
45 aminoethylcarbazol, diaminobenzidine, D-luciferin, luci­
genin (bis-I\Mnethylacridinium nitrate), resorufin benzyl 
ether, luminol, Amplex Red reagent (10-acetyl-3,7-dihy­
droxyphenoxazine, TMB (3 ,3, 5, 5-tetramethy lbenzidine) 
and ABTS (2,2-Azine-di[3-ethylbenzthiazoline sulfonate]) 5) radioactivity. Other methods for labeling and detection
will be readily apparent to one skilled in the art.
Where the PDS/TTR complexes are contemplated to be 
detected in a clinical setting, the labels are preferably 
non-radioactive and readily detected without the necessity of 
sophisticated instrumentation. In certain embodiments, 
detection of the labels will yield a visible signal that is 
immediately discernable upon visual inspection. One 
example of detectable secondary labeling strategies uses an 
antibody that recognizes PDS/TTR complexes in which the 
antibody is linked to an enzyme (typically by recombinant or 
covalent chemical bonding). The antibody is detected when 
the enzyme reacts with its substrate, producing a detectable 
product. In certain embodiments, enzymes that can be 
conjugated to detection reagents of the invention include, 
e.g., �-galactosidase, luciferase, horse radish peroxidase,
and alkaline phosphatase. The chemiluminescent substrate
for luciferase is luciferin. One embodiment of a fluorescent
substrate for �-galactosidase is 4-methylumbelliferyl-�-D-
50 may be used as a substrate. Other label/substrate pairs 
include biotin/streptavidin and luciferase/luciferin. 
Binding Ligands 
The present method uses two types of binding ligands, 
i.e., a "trapping" (or "capturing") binding ligand and a
55 "probing" ( or "detecting") binding ligand. As used herein, 
the term "trapping binding ligand" means a binding ligand 
capable of binding to the lipocalin-PDS/TTR complex of 
interest in biosamples. The term "probing binding ligand" 
means a binding ligand capable of binding to the lipocalin-
60 PDS/TTR complex captured by the trapping binding ligand. 
In one embodiment, the binding ligand is an antibody. By 
"antibody" is meant an immunoglobulin protein which is 
capable of binding an antigen. Antibody as used herein is 
meant to include the entire antibody as well as any antibody 
65 fragments (e.g., F(ab')2, Fab', Fab, Fv) capable of binding 
the epitope, antigen or antigenic fragment of interest. As 
used herein, the term "monoclonal antibody" refers to an 
US 9,835,621 B2 
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antibody obtained from a group of substantially homoge­
neous antibodies, that is, an antibody group wherein the 
antibodies constituting the group are homogeneous except 
for naturally occurring mutants that exist in a small amount. 
Monoclonal antibodies are highly specific and interact with 
8 
sequence. A "fully humanized antibody" is created in a 
hybridoma from mice genetically engineered to have only 
human-derived antibody genes or by selection from a phage­
display library of human-derived antibody genes. 
As used herein, the term "antibody" includes a single­
chain variable fragment (scFv), humanized, fully human or 
chimeric antibodies, single-chain antibodies, diabodies, and 
antigen-binding fragments of antibodies (e.g., Fab frag­
ments). A scFv is a fusion protein of the variable region of 
a single antigenic site. Furthermore, each monoclonal anti­
body targets a single antigenic determinant ( epitope) on an 
antigen, as compared to common polyclonal antibody prepa­
rations that typically contain various antibodies against 
diverse antigenic determinants. In addition to their specific­
ity, monoclonal antibodies are advantageous in that they are 
produced from hybridoma cultures not contaminated with 
other immunoglobulins. 
The adjective "monoclonal" indicates a characteristic of 
antibodies obtained from a substantially homogeneous 
group of antibodies, and does not specify antibodies pro­
duced by a particular method. For example, a monoclonal 
antibody to be used in the present invention can be produced 
by, for example, hybridoma methods (Kohler and Milstein, 
Nature 256:495, 1975) or recombination methods (U.S. Pat. 
No. 4,816,567). The monoclonal antibodies used in the 
present invention can be also isolated from a phage antibody 
library (Clackson et al., Nature 352:624-628, 1991; Marks et 
al., J. Mo!. Biol. 222:581-597, 1991). The monoclonal 
antibodies of the present invention particularly comprise 
"chimeric" antibodies (immunoglobulins), wherein a part of 
10 the heavy (V H) and light chains (V L) of an immunoglobulin 
that is connected by means of a linker peptide. The linker is 
usually short, about 10-25 amino acids in length. If flex­
ibility is important, the linker will contain a significant 
number of glycine. If solubility is important, serines or 
15 theonines will be utilized in the linker. The linker may link 
the amino-terminus of the V H to the carboxy-terminus of the 
VD or the linker may link the carboxy-terminus of the V H to 
the amino-terminus of the VL. Divalent (also called bivalent) 
scFvs can be generated by linking two scFvs. For example, 
20 a divalent scFv can be made by generating a single peptide 
containing two V Hand two VL regions. Alternatively, two
peptides, each containing a single V Hand a single V L region 
can be dimerized (also called "diabodies"). Bolliger et al., 
"Diabodies: small bivalent and bispecific antibody frag-
25 ments," PNAS, July 1993, 90:6444-6448. Bivalency allows 
antibodies to bind to multimeric antigens with high avidity, 
and bispecificity allows the cross-linking of two antigens. a heavy (H) chain and/or light (L) chain is derived from a 
specific species or a specific antibody class or subclass, and 
the remaining portion of the chain is derived from another 
species, or another antibody class or subclass. Furthermore, 30 
mutant antibodies and antibody fragments thereof are also 
comprised in the present invention (U.S. Pat. No. 4,816,567; 
Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855, 
1984). 
As used herein, the term "mutant antibody" refers to an 35 
antibody comprising a variant amino acid sequence in which 
one or more amino acid residues have been altered. For 
example, the variable region of an antibody can be modified 
to improve its biological properties, such as antigen binding. 
Such modifications can be achieved by site-directed muta- 40 
genesis (see Kunkel, Proc. Natl. Acad. Sci. USA 82: 488 
(1985)), PCR-based mutagenesis, cassette mutagenesis, and 
the like. Such mutants comprise an amino acid sequence 
which is at least 70% identical to the amino acid sequence 
of a heavy or light chain variable region of the antibody, 45 
more preferably at least 75%, even more preferably at least 
80%, still more preferably at least 85%, yet more preferably 
at least 90%, and most preferably at least 95% identical. As 
used herein, the term "sequence identity" is defined as the 
percentage of residues identical to those in the antibody's 50 
original amino acid sequence, determined after the 
sequences are aligned and gaps are appropriately introduced 
to maximize the sequence identity as necessary. Methods of 
producing monoclonal, polyclonal and mutant antibodies 
can be found in US Patent Publication No. 2011-0135689 55 
Al, which is incorporated by reference herein. 
Solid Substrates 
According to one embodiment, the trapping binding 
ligand is bound to a solid substrate. Known materials of this 
type include hydrocarbon polymers such as polystyrene and 
polypropylene, glass, metals, and gels. The solid substrate 
may be in the form of a dipstick, a microtiter plate, a particle 
(e.g., bead), an affinity colunm and an immunoblot mem-
brane (e.g., polyvinylidene fluoride membrane) (see U.S. 
Pat. Nos. 5,143,825; 5,374,530; 4,908,305 and 5,498,551). 
In certain embodiments, the solid substrate is a microtiter 
plate. 
According to one embodiment, the solid substrate bound 
to trapping ligands is a bead such as gelatin, latex, polysty­
rene, colloidal gold or a magnetic bead. The size of these 
beads may be in the range of 0.3 nm to 20 µm in diameter, 
and an optimal size can be selected according to the evalu­
ation method to be used. For example, for macroscopic 
evaluation, it is desirable to employ carriers of 0.2 to 3 µm 
in diameter with which macroscopic judgment is easier. 
Detection Methods and Assays 
The present invention provides methods for detecting a 
complex comprising PDS/TTR in a sample or in vivo. In 
certain embodiments, Western blots may be used to deter­
mine the presence and/or quantity of PDS/TTR in the 
sample. In certain embodiments or a competitive assay (for 
example, radioimmunoassay) may be used to determine the 
presence and/or quantity of PDS/TTR in the sample. For 
example, one can contact a sample with a binding ligand that 
is specific for PDS and subsequently contact the bound 
sample with a binding ligand that is specific for TTR, and 
detecting the presence or the quantity of bound PDS/TTR. In 
certain embodiments, the PDS/TTR is detected by means of 
As used herein, the term "antibody" includes scFv, 
humanized, fully human or chimeric antibodies, single­
chain antibodies, diabodies, and antigen-binding fragments 
of antibodies ( e.g., Fab fragments). In certain embodiments, 
the antibody is a human antibody or a humanized antibody. 
A "humanized" antibody contains only the three CDRs 
(complementarity determining regions) and sometimes a 
few carefully selected "framework" residues (the non-CDR 
portions of the variable regions) from each donor antibody 
variable region recombinantly linked onto the corresponding 
frameworks and constant regions of a human antibody 
60 nuclear magnetic resonance, fluorescent capillary electro­
phoresis, lateral flow devices, colorimetry, chemilumines­
cence, fluorescence, western blots, microarrays, enzyme 
linked immunosorbent assay (ELISA), radioHPLC, single 
photon emission computed tomography (SPECT), or posi-
65 tron emission tomography (PET), radioimmunoassay (RIA), 
immunoradiometric assay, fluoroimmunoassay, chemilumi­
nescent assay, and bioluminescent assay, though several 
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others are well known to those of ordinary skill. The steps 
of various useful immunodetection methods have been 
described in the scientific literature. 
In general, the detection of immunocomplex formation is 
well known in the art and may be achieved through the 
application of numerous approaches. These methods are 
generally based upon the detection of a label or marker, such 
10 
tion using tissue sections is also particularly useful. How­
ever, it will be readily appreciated that detection is not 
limited to such techniques, and/or western blotting, dot 
blotting, FACS analyses, and/or the like may also be used. 
as any of those radioactive, fluorescent, biological and 
enzymatic tags. U.S. patents concerning the use of such 
labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939, 
350; 3,996,345; 4,277,437; 4,275,149 and 4,366,241, each 
incorporated herein by reference. Of course, one may find 
additional advantages through the use of a secondary bind­
ing ligand such as a second antibody and/or a biotin/avidin 
ligand binding arrangement, as is known in the art. 
The diagnostic assay format that may be used in the 
present invention could take any conventional format such 
as ELISA or other platforms such as luminex or biosensors. 
The present invention detects the presence of a PDS/TTR 
complex. This sequence can readily be modified to facilitate 
10 diagnostic assays, for example a tag (such as GFP) can be 
added to the targeting antibody to increase sensitivity. In one 
exemplary ELISA, antibodies are immobilized onto a 
selected surface exhibiting protein affinity, such as a well in 
Further methods include the detection of primary immune 
complexes by a two-step approach. A second binding ligand, 
such as an antibody, that has binding affinity for the PDS/ 
TTR is used to form secondary immune complexes, as 
described above. After washing, the secondary immune 
complexes are contacted with a third binding ligand or 
antibody that has binding affinity for the second antibody, 
again under effective conditions and for a period of time 
sufficient to allow the formation of immune complexes 
(tertiary immune complexes). The third ligand or antibody is 
linked to a detectable label, allowing detection of the tertiary 
immune complexes thus formed. This system may provide 
for signal amplification if this is desired. 
15 a polystyrene microtiter plate. Then, a test composition 
suspected of containing the PDS/TTR complex, such as a 
clinical sample (e.g., a biological sample obtained from the 
subject), is added to the wells. After binding and/or washing 
to remove non-specifically bound immune complexes, the 
20 bound antigen may be detected. Detection is generally 
achieved by the addition of another antibody that is linked 
to a detectable label. This type of ELISA is a simple 
"sandwich ELISA." Detection may also be achieved by the 
addition of a second antibody, followed by the addition of a 
25 third antibody that has binding affinity for the second 
antibody, with the third antibody being linked to a detectable 
label. 
One method of immunodetection designed by Charles 
Cantor uses two different antibodies. A first step bioti- 30 
nylated, monoclonal or polyclonal antibody is used to detect 
the target antigen(s ), and a second step antibody is then used 
to detect the biotin attached to the complexed binding 
ligand. In this method the sample to be tested is first 
incubated in a solution containing the first step antibody. If 35 
the target antigen is present, some of the antibody binds to 
the antigen to form a biotinylated antibody/antigen complex. 
The antibody/antigen complex is then amplified by incuba­
tion in successive solutions of streptavidin ( or avidin), 
biotinylated DNA, and/or complementary biotinylated 40 
DNA, with each step adding additional biotin sites to the 
antibody/antigen complex. The amplification steps are 
repeated until a suitable level of amplification is achieved, at 
which point the sample is incubated in a solution containing 
the second step antibody against biotin. This second step 45 
antibody is labeled, as for example with an enzyme that can 
In another exemplary ELISA, the samples suspected of 
containing the antigen are immobilized onto the well surface 
and/or then contacted with binding agents. After binding 
and/or washing to remove non-specifically bound immune 
complexes, the bound anti-binding agents are detected. 
Where the initial binding agents are linked to a detectable 
label, the immune complexes may be detected directly. 
Again, the immune complexes may be detected using a 
second antibody that has binding affinity for the first binding 
agents, with the second antibody being linked to a detectable 
label. 
Another ELISA in which the antigens are immobilized, 
involves the use of antibody competition in the detection. In 
this ELISA, labeled antibodies against an antigen are added 
to the wells, allowed to bind, and/or detected by means of 
their label. The amount of an antigen in an unknown sample 
is then determined by mixing the sample with the labeled 
antibodies against the antigen during incubation with coated 
wells. The presence of an antigen in the sample acts to 
reduce the amount of antibody against the antigen available 
for binding to the well and thus reduces the ultimate signal. 
be used to detect the presence of the antibody/antigen 
complex by histoenzymology using a chromogen substrate. 
With suitable amplification, a conjugate can be produced 
which is macroscopically visible. 50 This is also appropriate for detecting antibodies against an 
antigen in an unknown sample, where the unlabeled anti­
bodies bind to the antigen-coated wells and also reduces the 
amount of antigen available to bind the labeled antibodies. 
Another known method of immunodetection takes advan­
tage of the immuno-PCR (Polymerase Chain Reaction) 
methodology. The PCR method is similar to the Cantor 
method up to the incubation with biotinylated DNA, how­
ever, instead of using multiple rounds of streptavidin and 55 
biotinylated DNA incubation, the DNA/biotin/streptavidin/ 
antibody complex is washed out with a low pH or high salt 
buffer that releases the antibody. The resulting wash solution 
is then used to carry out a PCR reaction with suitable 
primers with appropriate controls. At least in theory, the 60 
enormous amplification capability and specificity of PCR 
can be utilized to detect a single antigen molecule. 
As detailed above, immunoassays, in their most simple 
and/or direct sense, are binding assays. Certain preferred 
immunoassays are the various types of enzyme linked 65 
immunosorbent assays (ELISAs) and/or radioimmunoas­
says (RIA) known in the art. Immunohistochemical detec-
Irrespective of the format employed, ELISAs have certain 
features in common, such as coating, incubating and bind­
ing, washing to remove non-specifically bound species, and 
detecting the bound immune complexes. 
In coating a plate with anti-PDS or anti-TTP antibodies, 
one will generally incubate the wells of the plate with a 
solution of the antigen or antibodies, either overnight or for 
a specified period of hours. The wells of the plate will then 
be washed to remove incompletely adsorbed material. Any 
remaining available surfaces of the wells are then "coated" 
with a nonspecific protein that is antigenically neutral with 
regard to the test antisera. These include bovine serum 
albumin (BSA), casein or solutions of milk powder. The 
coating allows for blocking of nonspecific adsorption sites 
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on the innnobilizing surface and thus reduces the back­
ground caused by nonspecific binding of antisera onto the 
surface. 
In ELISAs, it is probably more customary to use a 
secondary or tertiary detection means rather than a direct 
procedure. Thus, after binding of a protein or antibody to the 
well, coating with a non-reactive material to reduce back­
ground, and washing to remove unbound material, the 
immobilizing surface is contacted with the biological sample 
12 
second concentration of PDS/TTR complex in a blood 
sample or urine sample from an unaffected individual, and 
( c) comparing the first and second concentrations, wherein
a lower first concentration as compared to the second
concentration is indicative of the subject having or being at
risk of developing Alzheimer's disease.
Aspect 2. A method of detecting a concentration of a 
biomarker in a human subject having or being at risk of 
developing Alzheimer's disease or Mild Cognitive Impair­
ment (MCI), the method comprising: (a) detecting a con­
centration oflipocalin-PDS/TTR complex in a blood sample 
or urine sample from the subject, (b) comparing the con­
centration to a reference value, wherein a lower concentra­
tion as compared to the reference value is indicative of the 
to be tested under conditions effective to allow innnune 10 
complex (antigen/antibody) formation. Detection of the 
immune complex then requires a labeled secondary binding 
ligand or antibody, and a secondary binding ligand or 
antibody in conjunction with a labeled tertiary antibody or a 
third binding ligand. 
"Under conditions effective to allow innnune complex 
(antigen/antibody) formation" means that the conditions 
preferably include diluting the PDS/TTR complex with 
solutions such as BSA, bovine gannna globulin (BGG) or 
phosphate buffered saline (PBS)/Tween. These added agents 20 
also tend to assist in the reduction of nonspecific back­
ground. 
15 subject having or being at risk of developing Alzheimer's 
disease or MCI. 
The "suitable" conditions also mean that the incubation is 
at a temperature or for a period of time sufficient to allow 
effective binding. Incubation steps are typically from about 25 
1 to 2 to 4 hours or so, at temperatures preferably on the 
order of 25° C. to 27° C., or may be overnight at about 4° 
C. or so.
Following all incubation steps in an ELISA, the contacted
surface is washed so as to remove non-complexed material. 30 
An example of a washing procedure includes washing with 
a solution such as PBS/Tween, or borate buffer. Following 
the formation of specific innnune complexes between the 
test sample and the originally bound material, and subse­
quent washing, the occurrence of even minute amounts of 35 
immune complexes may be determined. 
To provide a detecting means, the second or third anti­
body will have an associated label to allow detection. This 
may be an enzyme that will generate color development 
upon incubating with an appropriate chromogenic substrate. 40 
Thus, for example, one will desire to contact or incubate the 
first and second innnune complex with a urease, glucose 
oxidase, alkaline phosphatase or hydrogen peroxidase-con­
jugated antibody for a period of time and under conditions 
that favor the development of further innnune complex 45 
formation ( e.g., incubation for 2 hours at room temperature 
in a PBS-containing solution such as PBS-Tween). 
After incubation with the labeled antibody, and subse­
quent to washing to remove unbound material, the amount 
oflabel is quantified, e.g., by incubation with a chromogenic 50 
substrate such as urea, or bromocresol purple, or 2,2'-azino­
di-(3-ethyl-benzthiazoline-6-sulfonic acid (ABTS), or 
H202, in the case of peroxidase as the enzyme label. 
Quantification is then achieved by measuring the degree of 
color generated, e.g., using a visible spectra spectrophotom- 55 
eter. 
Aspect 3. The method of Aspect 1 or Aspect 2, wherein 
the blood sample is a sample of whole blood, seruni, plasma, 
or a subcomponent of blood. 
Aspect 4. The method of any one of Aspects 1 to 3, 
wherein the blood sample is a serum or plasma sample. 
Aspect 5. The method of any one of Aspects 1 to 4, 
wherein the lipocalin-PDS/TTR complex is a trimer con­
sisting of one molecule of lipocalin-PDS and two molecules 
ofTTR. 
Aspect 6. The method of any one of Aspects 1 to 5, 
wherein the lipocalin-PDS/TTR complex binds to a trapping 
binding ligand specific for lipocalin-PDS but not to a 
binding ligand specific for hematopoietic-PDS/TTR com­
plex. 
Aspect 7. The method of Aspect 6, wherein the binding 
ligand is an antibody. 
Aspect 8. The method of any one of Aspects 1 to 7, 
wherein the lipocalin-PDS/TTR complex is a modified 
lipocalin-PDS/TTR complex that further comprises alpha 
and/or beta-unsaturated aldehydic by-products of lipid per-
oxidation. 
Aspect 9. The method of any one of Aspects 1 to 8, 
wherein the lipocalin-PDS/TTR complex binds to a probing 
binding ligand specific for TTR. 
Aspect 10. The method of Aspect 9, wherein the probing 
ligand specific for TTR further comprises a label generating 
a detectable signal. 
Aspect 11. The method of Aspect 10, wherein the label 
comprises a chemical, an enzymatic, a radioactive, a fluo­
rescent, a luminescent, a chemiluminescent and a FRET 
label. 
Aspect 12. The method of any one of Aspects 1 to 11, 
wherein the detection of the first concentration of lipocalin­
PDS/TTR complex is by ELISA. 
Aspect 13. A kit comprising (a) a solid substrate; (b) a 
trapping binding ligand specific for lipocalin-PDS bound to 
the solid substrate; (c) a probing binding ligand specific for 
TTR; ( d) optionally, instructions for using the kit to detect 
PDS/TTR in a blood sample or urine sample. 
Aspect 14. The kit of Aspect 13, wherein the solid 
substrate is a hydrocarbon polymer, glass, metal, or gel. 
ASPECTS OF THE INVENTION 
Accordingly, the invention can be seen, inter alia, in the 
following Aspects: 
Aspect 15. The kit of Aspect 13, wherein the solid 
substrate is a gelatin, latex, polystyrene, colloidal gold or a 
60 magnetic bead. 
Aspect 1. A method of detecting a concentration of a 
biomarker in a human subject having or being at risk of 
developing Alzheimer's disease or Mild Cognitive Impair­
ment (MCI), the method comprising: (a) detecting a first 
concentration of lipocalin-PDS/TTR complex in a blood 
sample or urine sample from the subject, (b) determining a 
Aspect 16. The kit of any one of Aspects 13 to 15, wherein 
trapping binding ligand specific for lipocalin-PDS but not to 
a binding ligand specific for hematopoietic-PDS. 
Aspect 17. A method of isolating a lipocalin-PDS/TTR 
65 complex biomarker from blood or urine comprising: (a) 
contacting the blood or urine with a trapping binding ligand 
specific for lipocalin-PDS to form a trapped biomarker, 
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wherein the trapping binding ligand specific for lipocalin­
PDS is bound to a solid substrate; (b) contacting the trapped 
biomarker with a probing binding ligand that is specific for 
TTR to form a probed biomarker complex; and ( c) purifying 
the probed biomarker complex. 
Aspect 18. A probed biomarker complex isolated accord­
ing to the method of Aspect 17. 
14 
through aldehydic crosslinking of one molecule of brain­
specific (lipocalin) PDS and one dimer of TTR delineate 
between normal control (NC) subjects and patients with 
mild cognitive impairment (MCI) and/or probable Alzheim-
5 er's disease (AD). To determine if the PDS/TTR complex 
was present in serum of AD and NC subjects the inventors 
carried out immunoprecipitation studies of serum samples 
from three representative normal control (NC) subjects and 
3 representative probable AD patients using rabbit anti-TTR 
10 as the trap antibody and mouse anti-lipocalin PDS as the 
probe antibody. 
Aspect 19. A process for detecting Alzheimer's disease 
(AD) or Mild Cognitive Impairment (MCI) in a human 
subject, the process comprising obtaining a sample of blood 
from the subject, preparing a sample of serum from the 
sample of blood, determining the concentration of PDS/TTR 
in the sample of serum, and comparing the concentration of 
PDS/TTR to a reference value. 
FIG. 1 shows the presence of a band at -55 kDa corre­
sponding to 1 molecule of PDS (23 kDa) crosslinked with 1 
Aspect 20. The process of Aspect 19, wherein AD or MCI 15 dimer (32 kDa) of TTR in serum samples and that levels are 
is detected if the concentration of PDS/TTR is less than the significantly (p<0.05) lower in probable AD patients 
reference value. 
Aspect 21. The process of Aspect 19 or 20, wherein the 
sample of blood is collected from the subject by phlebotomy. 
Aspect 22. The process of any one of Aspects 19 to 21, 
wherein the sample of serum is prepared from the sample of 
blood by permitting the sample of blood to clot and centri­
fuging the sample of blood. 
Aspect 23. The process of any one of Aspects 19 to 22, 
wherein the concentration of PDS/TTR in the sample of 
serum is determined by ELISA. 
Aspect 24. The process of any one of Aspects 19 to 23, 
wherein the ELISA is an ELISA described in U.S. Pat. No. 
7,851,172. 
Aspect 25. The process of any one of Aspects 19 to 24, 
wherein the ELISA provides an electromagnetic signal 
capable of being detected by an optical reader. 
Aspect 26. The process of any one of Aspects 19 to 25, 
wherein the ELISA provides an electrochemical signal 
capable of being detected by an electrochemical signal 
detection apparatus. 
The invention now will be described more fully herein­
after. In particular, aspects of the invention are more fully 
illustrated by the following examples, set forth to illustrate 
(35.1±2.5% control) compared to NC subjects (100±2.9%). 
To further verify our hypothesis that levels of the PDS/TTR 
complex decrease in serum as they increase in CSF in 
20 MCI/AD, we used our previously described enzyme linked 
immunoassay (ELISA) developed for use with CSF speci­
mens (with slight modification for serum analyses) to quan­
tify levels of the PDS/TTR complex in postmortem ven­
tricular CSF and antemortem serum from 11 autopsy-
25 verified NC subjects and 5 MCI patients and found a strong 
negative correlation between CSF and serum levels of the 
complex for MCI patients (r=-0.76) but not for NC subjects 
(r=0.28). Based on these data, we used a PDS/TTR ELISA 
to analyze antemortem plasma specimens from 7 6 living NC 
30 subjects (43M/33W) and 45 MCI (26M/19W) patients. 
Subject demographic data are shown in Table 1. MCI 
subjects were significantly older and showed significantly 
lower MMSE scores compared to NC subjects. There was no 
difference in baseline MMSE scores of NC subjects who 
35 converted to MCI compared to those who remained controls. 
Table 1 shows there was a significant decrease in PDS/TTR 
concentrations in MCI subjects 356.5±11.9 ng/ml) com­
pared to age-matched NC subjects (621.8±34.7 ng/ml) but 
no significant difference in A� 1_42 levels. 
TABLE 1 
Subject demographic data, PDS/TTR and ABl-42 concentrations. 
Mean± SEM 
Mean± SEM Mean± SEM PDS/TTR Complex Mean± SEM 
Age (y) Sex MMSE (ng/ml) Al31-42(pg/ml) 
NC (N - 76) 
MCI (N- 45) 
75.2 ± 0.8 43M/33W 29.1 ± 0.1 621.8 ± 34.7 22.0 ± 2.2 
79.9 0.9* 26M/19W 19.7 ± 1.6* 356.5 ± 11.9* 20.9 ± 2.8 
NC - NC (n - 37) 
NC - MCI (n - 29) 
72.9 ± 1.0 19M/18W 29.2 ± 0.1 660.6 ± 36.7 23.1 ± 3.7 
77.9 ± 1.1 * 17M/12W 28.6 ± 0.4 451.3 ± 42.1 * 23.1 ± 4.6 
*p < 0.05 
certain aspects of the present invention and not to be 
construed as limiting thereof. The invention may, however, 
be embodied in many different forms and should not be 
construed as limited to the embodiments set forth herein; 
rather, these embodiments are provided so that this disclo­
sure will be thorough and complete, and will fully convey 
the scope of the invention to those skilled in the art. As used 
in this specification and the claims, the singular forms "a," 
"an," and "the" include plural referents unless the context 
clearly dictates otherwise. 
Example 1 
The following experiments were carried out to verify that 
serum concentrations of a protein/protein complex formed 
Reporter operator curves (ROC) (FIG. 2) for comparison 
55 
of the sensitivity/specificity for the identification of MCI 
patients from NC subjects for both PDS/TTR and A� 1_42 
showed the PDS/TTR complex had an area under the curve 
(AUC) of 84% (p<0.001) with a sensitivity and specificity of 
70% for the identification of MCI patients from NC subjects 
60 (cutoff=402.6 ng/ml). In contrast, A� 1_42 results showed an 
AUC of 44.6% with a sensitivity of 52% and a specificity of 
44% for the same plasma samples. 
The major difficulty in the development of a serum based 
bioassay for AD that relies on quantification of levels of 
65 brain specific proteins (lipocalin PDS) is the potential inter­
ference by blood associated proteins specifically hematopoi­
etic (glutathione-dependent) PDS and additional TTR pres-
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ent in serum. To verify that our lipocalin-specific PDS 
antibody does not cross react with hematopoietic PDS, we 
subjected recombinant lipocalin and hematopoietic PDS to 
SDS-PAGE. FIG. 3A shows a Coomassie blue stained gel of 
hematopoietic PDS in Lane 1 and lipocalin PDS in Lane 2. 
FIG. 38 shows a Western blot of a separate gel stained using 
the anti-lipocalin PDS antibody. These figures demonstrate 
the lipocalin PDS antibody is specific for brain associated 
lipocalin PDS. To further verify that the presence of 
hematopoietic PDS or increased levels of TTR in serum do 
not interfere with quantification of lipocalin PDS using our 
ELISA we analyzed a representative serum sample alone or 
in the presence of recombinant hematopoietic PDS or TTR 
at concentrations between 15.75 ng/ml and 2000 ng/ml. 
Table 2 shows there were no significant differences in 
response of the ELISA in the presence of hematopoietic PDS 
or TTR even at 2000 ng/ml. 
TABLE 2 
16 
rology, 1984. 34(7): p. 939-44). In addition, current clinical 
diagnostic methods are not foolproof with accuracies 
between 65% and 90% (reviewed in Andreasen, N. and K. 
Blennow, CSP biomarkers for mild cognitive impairment 
and early Alzheimer's disease. Clin Neural Neurosurg, 
2005. 107(3): p. 165-73; Davidsson, P. and M. Sjogren, 
Proteome studies of CSP in AD patients. Mech Ageing Dev, 
2006. 127(2): p. 133-7; de Leon, M. J., et al., Longitudinal 
CSP and MRI biomarkers improve the diagnosis of mild 
10 cognitive impairment. Neurobiol Aging, 2006. 27(3): p. 
394-401; Maccioni, R. B., et al., Biological markers of
Alzheimer's disease and mild cognitive impairment. Curr
Alzheimer Res, 2004. 1(4): p. 307-14) with higher rates
associated with specialized memory disorder clinics,
15 whereas lower rates are associated with primary care clinics. 
Also, the accuracy of clinical diagnosis of AD is likely lower 
during prodromal stages of the disease or for older, or poorly 
Mean ± SEM ELISA response (% Control) for a representative serum sample 
probed witbout added hematopoietic PDS or TTR (Control) or in tbe presence of hematopoietic 
PDS or TTR at concentrations from 15.75 ng/ml to 2000 ng/ml. The presence of hematopoietic 
PDS or additional TTR did not significantly change tbe ELISA response at any concentration. 
Concentration (ng/ml) 
0 15.75 31.5 62.5 125 250 500 1000 2000 
Hematopoietic 100 ± 103.3 ± 100.7 ± 99.7 ± 100.7 ± 100.7 ± 107.8 ± 95.2 ± 93.9 ± 
PDS 1.2% 2.6% 4.0% 4.2% 5.3% 8.6% 5.2% 18.8% 11.7% 
TTR 100 ± 119.1 ± 105.0 ± 101.7 ± 100.0 ± 110.4± 108.3 ± 109.8 ± 112.9 ± 
1.2% 8.2% 3.6% 4.3% 6.7% 6.5% 
Sample Processing: Blood samples were drawn from 
subjects. Blood samples were allowed to clot for 1 hour and 
centrifuged at 3,000xg for 5 minutes to separate serum. The 
serum was aliquoted into 1 ml single use aliquots and stored 
at -80° C. in the UK-ADC tissue repository until used for 
analysis. 
ELISA Analyses: Quantification of PDS/TTR levels was 
carried out by generally following the inventors' ELISA that 
traps PDS and quantifies TTR complexed with the PDS 
described in U.S. Pat. No. 7,851,172, fully incorporated by 
reference herein. Samples were analyzed in triplicate and in 
a blind fashion. Because of the high protein content of serum 
samples SynB!ock (Serotec) was used as a blocking agent 
and for dilution of trap and detection antibodies. Addition­
ally, serum samples were diluted in 50 µl antigen capture 
buffer (5 mM NaH2P04, 15 mM Na2P04, 2 mM EDTA, 0.4 
M NaCl, 0.5% CHAPS, 0.2% bovine serum albumin and 
0.4% BSA block (Serotec) (pH 7.0) for analysis. All other 
parameters were as previously described. To allow compari­
son across plates, a representative quality control serum 
sample can be analyzed on all plates as an internal control 
specimen. 
Example 2 
Currently, clinical diagnosis of AD is based on physical 
and neurological examinations and neuropsychological 
examinations coupled with neuroimaging (structural and 
functional MRI, CT, PET and/or SPECT scans). Unfortu­
nately, using current diagnostic criteria, AD is not defini­
tively diagnosed until the disease has progressed to pro­
nounced dementia (McKhann, G., et al., Clinical diagnosis 
of Alzheimer's disease: report of the NIN CDS-AD RDA Work 
Group under the auspices of Department of Health and 
Human Services Task Force on Alzheimer's Disease. Neu-
3.5% 3.4% 5.4% 
educated subjects (reviewed in (de Leon, M. J., et al., 
Longitudinal CSP and MRI biomarkers improve the diag-
35 nos is of mild cognitive impairment. Neurobiol Aging, 2006. 
27(3): p. 394-401). With increasing availability of poten­
tially beneficial therapeutics, patients are seeking medical 
intervention at earlier stages of the disease. Previous studies 
suggest preclinical stages of AD may begin 20 to 30 years 
40 before onset of clinical symptoms (reviewed Blennow, K.,
Cerebrospinal fluid protein biomarkers for Alzheimer's dis­
ease. NeuroRx, 2004. 1(2): p. 213-25) and that during this 
prodromal phase, neuronal degeneration and senile plaque 
(SP) formation increase until a threshold is reached where 
45 
episodic memory impairment occurs, a transition between 
normal aging and dementia described as amnestic mild 
cognitive impairment (MCI). 
Difficulties associated with diagnosis of AD has generated 
considerable interest in the identification of a reliable protein 
based biomarkers of AD that could aid clinicians in more 
50 readily diagnosing AD at earlier stages before symptoms of 
dementia appear (Davidsson, P. and M. Sjogren, Proteome 
studies of CSP in AD patients. Mech Ageing Dev, 2006. 
127(2): p. 133-7). Ideally, these biomarkers are character­
istic molecules, typically proteins or protein fragments, that 
55 are based on some fundamental feature of AD neuropathol­
ogy and can be objectively measured and evaluated in a 
reasonably sampled body fluid as an indicator of a patho­
genic process or the response to therapeutic interventions 
(reviewed in Andreasen, N. and K. Blennow, CSP biomark-
60 ers for mild cognitive impairment and early Alzheimer's 
disease. Clin Neural Neurosurg, 2005. 107(3): p. 165-73; de 
Leon, M. J., et al., Longitudinal CSP and MRI biomarkers 
improve the diagnosis of mild cognitive impairment. Neu­
robiol Aging, 2006. 27(3): p. 394-401; Maccioni, R. B., et 
65 al., Biological markers of Alzheimer's disease and mild 
cognitive impairment. Curr Alzheimer Res, 2004. 1(4): p. 
307-14).
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Current Biomarkers of AD in Blood 
Although multiple potential biomarkers of AD have been 
identified and studied in CSF, lumbar puncture is not a 
widespread practice in primary care or geriatric clinics and 
18 
plasma. Studies of IL-6 in blood have been contradictory 
with reports of elevations in AD or no changes. Similar 
results have been observed for several other cytokines 
including TNF-a and TGF-�. In more recent studies (Ray et 
al., Classification and prediction of clinical Alzheimer's 
diagnosis based on plasma signaling proteins. Nat Med, 
2007. 13(11): p. 1359-62) using a multiplex analysis iden­
tified multiple signaling proteins in plasma including 
G-CSF, IL-la, IL-3, IL-11, GM-CSF, PDGF-BB and TNFa
is not routinely carried out during evaluation of AD patients. 5 
Therefore, biomarkers of AD in blood (serum or plasma) 
that would allow more widely applicable, minimally inva­
sive and less expensive testing of patients are critically 
needed. The primary difficulty in the development of a 
serum based AD diagnostic is the physiology of the blood­
brain and blood-CSP barriers that typically limits the trans­
fer of potentially diagnostic molecules to the blood. Addi­
tionally, dilution of brain specific proteins or protein 
fragments in blood make detection more difficult. Currently, 
the most widely studied potential biomarkers of AD in blood 15 
include those related to A� processing (A�1 _42, A� 1_40 and
the ratio of A�1 _42/A� 1_40) and inflammation. 
10 that in combination, differentiated patients with AD from
age-matched NC subjects.
A� as a Biomarker 
As observed for CSF, diminished levels of A�1 _42 in blood 
are thought to reflect deposition in SP in the brain. Com- 20 
parison of blood and CSF levels of A� shows a 100-fold 
decrease in plasma compared to CSF (reviewed in Solfrizzi, 
There is considerable need for the identification and 
validation of alternative molecules that alone or in combi­
nation with others would allow non-invasive tests for early 
detection of AD. Based on our study demonstrating 
increased levels of an aberrant protein/protein complex 
consisting of 1 molecule of brain-specific (lipocalin) pros­
taglandin-d-synthase (PDS; Swiss-Prot#P41222) and 1 
dimer of transthyretin (TTR; Swiss-Prot#P02766) in CSF 
that delineated AD from NC and DC subjects (Lovell, M. A., 
et al., An aberrant protein complex in CSP as a biomarker 
of Alzheimer disease. Neurology, 2008. 70(23): p. 2212-8) 
coupled with preliminary unpublished data suggesting that 
cultured choroid plexus epithelial cells established from AD 
and MCI subjects lose their capacity to transport large 
molecules from brain compared to cultures from NC sub­
jects, we hypothesized that levels of the PDS/TTR complex 
would decrease in blood during disease progression and 
would likely reflect diminished choroid plexus function. 
Although glycosylation, phosphorylation, acetylation and 
oxidative modifications have been identified for specific 
isoforms of PDS in AD, PD, and ALS CSF (reviewed in 
V., et al., Circulating biomarkers of cognitive decline and 
dementia. Clin Chim Acta, 2006. 364(1-2): p. 91-112). 
Studies of the relationship between plasma A� and cognitive 25 
impairment have been contradictory. Multiple cross sec­
tional and longitudinal studies have shown evaluated plasma 
A� levels in MCI and AD whereas most show no differences 
between AD and NC subjects for A� 1_40 levels. Studies of 
A� 1_42 show similar results for AD and NC subjects 30 
although more recent longitudinal data suggest high plasma 
A� 1_42 levels were a risk factor for the development of AD. 
Case control studies of MCI and NC subjects showed lower 
A� 1_42 levels in MCI patients, although they did not corre­
late with disease progression or with severity of dementia. 
More recent studies show no significant differences in 
multiple A� species between AD and control groups 
although lower A� 1_4iA�N- 42 ratios were observed for 
demented (AD and non-AD) subjects compared to normal 
controls (Le Bastard, N., et al., Plasma amyloid-beta forms 40 
in Alzheimer's disease and non Alzheimer's disease patients. 
Journal of Alzheimer's disease: JAD, 2010. 21(1): p. 291-
301). Another study suggested high baseline plasma A�42 
and A�40 with decreasing A�42 levels on follow-up were 
associated with more pronounced decline in multiple cog- 45 
nitive domains (Cosentino, S. A., et al., Plasma ss-amyloid 
and cognitive decline. Archives of neurology, 2010. 67(12): 
35 Harrington, M. G., et al., Prostaglandin D synthase isoforms 
from cerebrospinal fluid vary with brain pathology. Dis 
Markers, 2006. 22(1-2): p. 73-81) the association of PDS 
with classical pathogenic cascades remains unclear. Simi-
p. 1485-90). 
Despite the initial promise associated with plasma A� as 
a biomarker of AD, current data suggest plasma A� levels 50 
alone do not demonstrate sufficient sensitivity or specificity 
as a diagnostic biomarker of AD. More recently, studies have 
focused on quantification of levels of APP in platelets which 
is cleaved following platelet activation to yield carboxy­
truncated fragments of 110 or 120 to 130 kDa and suggest 55 
a decrease in the 130 kDa/110 kDa ratio is present in MCI 
and AD patients but not in NC or patients with other 
neurological disorders. The APP isoform ratio correlated 
with disease progression and severity and demonstrated 
diagnostic sensitivities/specificities of 80-90% although the 60 
relationship between levels of platelet specific APP and 
brain alterations remains unclear. 
Inflammatory Cytokines as Biomarkers of AD 
Multiple studies show abnormal levels of various inflam­
matory cytokines in brain regions affected in AD. However, 65 
it remains unclear if accumulation of inflammatory mol­
ecules in brain would be reflected accurately in serum/ 
larly, TTR which is functionally active as a homotetramer 
composed of 4 monomers (MW=16 kDa) arranged as a 
dimer of dimers is of potential interest in AD because 
mutations of the TTR gene are the most common cause of 
autosomal dominant systemic amyloidoses underlying 
familial amyloid polyneuropathy (FAP) that is characterized 
by high abundance TTR present in �-structured fibrils. 
Diminished native TTR is suggested to negatively affect A� 
aggregation and alter thyroxine transport leading to neuro­
degeneration (Serot, J. M., et al., Cerebrospinal fluid tran­
sthyretin: aging and late onset Alzheimer's disease. J Neural 
Neurosurg Psychiatry, 1997. 63(4): p. 506-8). Although no 
mutations of TTR have been identified in AD, TTR over-
expression is neuroprotective in AD animal models (Stein, T. 
D., et al., Neutralization of transthyretin reverses the neu­
roprotective ef ects of secreted amyloid precursor protein 
(APP) in APP SW mice resulting in tau phosphorylation and 
loss of hippocampal neurons: support for the amyloid 
hypothesis. J Neurosci, 2004. 24(35): p. 7707-17). 
Considerable research effort has been directed at the study 
oflevels ofA� 1_42 and A�1 _40 or ratios of the two as potential 
diagnostic biomarkers of AD. Unfortunately, the studies are 
been somewhat contradictory leaving a need for evaluation 
of additional novel serum/plasma biomarkers of the disease. 
The aims described in this proposal are innovative in that 
they are directed at the potential diagnostic efficacy of a 
novel biomarker of disease that appears to have improved 
sensitivity/specificity compared to measures of A�. In addi-
tion, the proposed studies will evaluate potential synergies 
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between our novel biomarker and more established markers 
to evaluate potential enhancement of diagnostic efficacy of 
the individual measures. 
Immunoprecipitation studies of serum samples from 3 
representative NC subjects and 3 probable AD patients using 
mouse anti-PDS as the trap antibody and rabbit anti-TTR as 
the probe antibody, identified a band at-55 kDa correspond­
ing to 1 molecule of PDS (23 kDa) crosslinked with 1 dimer 
(32 kDa) of TTR in serum. Levels of the complex were 
significantly (p<0.05) lower in probable AD patients 10 
(35.1±2.5% control) compared to NC subjects (100±2.9%). 
20 
with immunizing peptides showed the lipocalin PDS anti­
body is specific for brain associated lipocalin PDS ( data not 
shown). Analysis of a representative plasma sample alone or 
with recombinant hematopoietic PDS or TTR added at 
concentrations between 15. 7 5 ng/ml and 2000 ng/ml showed 
no significant difference in response of the ELISA. 
Example 3 
To test if serum PDS/TTR complex concentrations 
decrease in the same person following conversion to MCI by 
To further verify our hypothesis that levels of the PDS/TTR 
complex decrease in serum as they increase in CSF in 
MCI/AD, we used our previously described enzyme linked 
immunoassay (ELISA) developed for use with CSF speci­
mens (Lovell, M. A., et al., An aberrant protein complex in 
CSP as a biomarker of Alzheimer disease. Neurology, 2008. 
70(23): p. 2212-8) (with slight modification for serum 
analyses) to quantify levels of the PDS/TTR complex in 
postmortem ventricular CSF and antemortem serum from 11 
autopsy-verified NC subjects and 5 MCI patients and found 
a strong negative correlation between CSF and serum levels 
15 analyzing pre- and post-conversion serum specimens from 
NC subjects who transitioned from normal to MCI or AD 
compared to results obtained for serum samples from control 
subjects who remained cognitively normal after a compa-
20
rable follow-up period. We analyzed plasma samples 
of the complex for MCI patients (r=-0.76) but not for NC 
subjects (r=0.28). To allow comparison of results of our 
PDS/TTR measures with the more established marker A�, 
we tested paired serum/plasma samples from probable AD 
and NC subjects and found that plasma concentrations of the 
complex were higher than those observed in serum. Based 
25 
obtained from 28 MCI patients before and after conversion 
from NC status to MCI and showed a significant 31.6±8.5% 
decrease in levels of PDS/TTR for MCI patients following 
conversion compared to 43 NC subjects who remained 
cognitively normal after a comparable follow-up period. 
Table 4 shows mean±SEM percent change in PDS/TTR 
concentrations, MMSE scores and A� levels and shows a 
significantly more pronounced change in PDS/TTR concen-on these data we used our PDS/TTR ELISA to analyze 
antemortem plasma specimens from 76 living NC subjects 
(43M/33W) and 45 MCI (26M/19W) patients. Subject 
demographic data are shown in Table 3. MCI subjects were 
significantly older and showed significantly lower MMSE 
scores compared to NC subjects. There was no difference in 
baseline MMSE scores of NC subjects who converted to 
MCI compared to those who remained controls. Table 3 
shows there was a significant decrease in PDS/TTR con­
centrations in MCI subjects 356.5±11.9 ng/ml) compared to 
age-matched NC subjects (621.8±34.7 ng/ml) but no sig­
nificant difference in A�1 _42 levels.
30 trations in MCI patients compared to changes in MMSE or 
A� levels suggesting levels of the complex may be a more 
sensitive indicator of disease progression. In addition, based 
on PDS/TTR concentrations measured in initial plasma 
35 draws we identified a subset of 10 NC subjects with unusu­
ally low PDS/TTR concentrations who remained cognitively 
TABLE 3 
normal at the second plasma draw but who showed signifi­
cantly diminished scores on logical memory tasks at subse­
quent draws. 
Subject demographic data, PDS/TTR and ABl-42 concentrations. 
NC (N - 76) 
MCI (N- 45) 
NC -NC (n - 37) 
NC -MCI (n - 29) 
*p < 0.05 
Mean± SEM 
Age (y) 
75.2 ± 0.8 
79.9 0.9* 
72.9 ± 1.0 
77.9±1.1* 
Mean± SEM 
Sex MMSE 
43M/33W 29.1 ± 0.1 
26M/19W 19.7 ± 1.6* 
19M/18W 29.2 ± 0.1 
17M/12W 28.6 ± 0.4 
Mean± SEM 
PDS/TTR Complex 
(ng/ml) 
621.8 ± 34.7 
356.5 ± 11.9* 
660.6 ± 36.7 
451.3 ± 42.1* 
NC-NC 
NC -MCI 
Mean± SEM 
Al31-42 (pg/ml) 
22.0 ± 2.2 
20.9 ± 2.8 
23.1 ± 3.7 
23.1 ± 4.6 
TABLE 4 
Mean ± SEM % Mean ± SEM % Mean ± SEM % 
Change PDS/TTR Change in Aj3142 Change in MMSE 
9.0 ± 5.3 
-22.3 ± 2.9* 
3.1 ± 1.3 
23.3 ± 13.4 
-1.2 ± 0.01 
-6.3 ± 1.5* 
Reporter operator curves (ROC) (FIG. 2) for comparison 
55 
of the sensitivity/specificity for the identification of MCI 
patients from NC subjects for both PDS/TTR and A� 1_42
showed the PDS/TTR complex had an area under the curve 
(AUC) of 84% (p<0.001) with a sensitivity and specificity of 
70% for the identification of MCI patients from NC subjects 60 
(cutoff=402.6 ng/ml). In contrast, A�1_42 results showed an 
AUC of 44.6% with a sensitivity of 52% and a specificity of 
44% for the same plasma samples. 
Mean ± SEM % change in PDS/TTR concentration is significantly larger than changes in 
MMSE or A� 1-42 levels. 
Potential interference by blood associated proteins, spe­
cifically hematopoietic (glutathione-dependent) PDS and 65 
additional TTR present in blood are potential analytical 
difficulties. Western blot analysis using antibodies blocked 
*p < 0.05. 
Overall, the data suggest that quantification of levels of 
the PDS/TTR complex in plasma may be effective in the 
identification of AD subjects including those early in disease 
progression (MCI patients). Early identification of AD 
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would allow pharmacologic interventions that could delay 
cognitive decline associated with AD and improve the 
quality of life for those subjects. The proposed test could 
also be used as a screen to better identify subjects for 
in�l�si?� in clinical trials of potential therapeutics thereby 
m1mm1zmg the number of subjects needed to insure a 
sufficient number of subjects convert to AD during the trial. 
In our preliminary studies, the PDS/TTR complex was 
reliable, reproducible, and provided the necessary sensitiv­
ity/specificity for the identification of subjects early in 10 
disease progression (MCI). 
Every reference cited herein is incorporated fully by 
reference. To the extent that there is any conflict between the 
t�aching of any reference and that of the instant specifica­
tion, the teaching of the instant specification shall control. 15 
Many modifications and other embodiments of the inven­
tion will come to mind to one skilled in the art to which this 
invention pertains having the benefit of the teachings pre­
sented in the foregoing description. Therefore, it is to be 
understood that the invention is not to be limited to the 20 
specific embodiments disclosed and that modifications and 
other embodiments are intended to be included within the 
scope of the appended claims. Although specific terms are 
employed herein, they are used in a generic and descriptive 
sense only and not for purposes of limitation. 25 
. Although the foregoing specification and examples fully
disclose and enable the present invention, they are not 
intended to limit the scope of the invention, which is defined 
by the claims appended hereto. 
All publications, patents and patent applications are incor- 30 
porated herein by reference. While in the foregoing speci­
fication this invention has been described in relation to 
certain embodiments thereof, and many details have been set 
forth for purposes of illustration, it will be apparent to those 
skilled in the art that the invention is susceptible to addi- 35 
tional embodiments and that certain of the details described 
herein may be varied considerably without departing from 
the basic principles of the invention. 
The use of the terms "a" and "an" and "the" and similar 
referents in the context of describing the invention are to be 40 
construed to cover both the singular and the plural, unless 
otherwise indicated herein or clearly contradicted by con­
text. The terms "comprising," "having," "including," and 
"containing" are to be construed as open-ended terms (i.e., 
meaning "including, but not limited to") unless otherwise 45 
�oted. Recitation of ranges of values herein are merely 
11:tended to serve as a shorthand method of referring indi­
vidually to each separate value falling within the range, 
unless otherwise indicated herein, and each separate value is 
incorporated into the specification as if it were individually 50 
recited herein. All methods described herein can be per­
formed in any suitable order unless otherwise indicated 
herein or otherwise clearly contradicted by context. The use 
of any and all examples, or exemplary language ( e.g., "such 
as") provided herein, is intended merely to better illuminate 55 
the )nvent)on and does not pose a limitation on the scope of 
the mvent10n unless otherwise claimed. No language in the 
spe_cification should be construed as indicating any non­
clmmed element as essential to the practice of the invention. 
Embodiments of this invention are described herein 60 
including the best mode known to the inventors for carryin� 
out the invention. Variations of those embodiments may 
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beco_me apparent to those of ordinary skill in the art upon 
re�dmg t�e foregoing description. The inventors expect 
skil�ed artisan� to employ such variations as appropriate, and 
the mventors mtend for the invention to be practiced other­
�ise t�an �s specifically described herein. Accordingly, this 
mvent10n mcludes all modifications and equivalents of the 
subject matter recited in the claims appended hereto as 
permitted by applicable law. Moreover, any combination of 
the above-described elements in all possible variations 
thereof is encompassed by the invention unless otherwise 
indicated herein or otherwise clearly contradicted by con­
text. 
The invention claimed is: 
1. A method of detecting lipocalin-prostaglandin-d-syn­
thase/transthyretin (PDS/TTR) biomarker complex in a 
human subject suspected of having Alzheimer's disease or 
mild cognitive impairment, comprising: 
(i) obtaining a blood sample or urine sample from the
human subject suspected of having Alzheimer's disease
or mild cognitive impairment; and
(ii) detecting the lipocalin-prostaglandin-d-synthase/tran­
sthyretin (PDS/TTR) complex in the blood sample or
urine sample from the subject by contacting the smnple
with a trapping binding ligand that is an anti-lipocalin­
PDS antibody followed by contacting the smnple from
the subject with a probing binding ligand that is an 
anti-TTR antibody to obtain a lipocalin-PDS/TTR
complex.
2. The method of claim 1, wherein the anti-lipocalin PDS
antibody is a mouse anti-lipocalin-PDS antibody, and the 
anti-TTR antibody is a rabbit anti-TTR antibody. 
3. The method of claim 1, wherein the blood sample is a
smnple of whole blood, serum, plasma, or a subcomponent 
of blood. 
4. The method of claim 1, wherein the blood sample is a
serum or plasma sample. 
5. The method of claim 1, wherein the probing binding
ligand specific for TTR further comprises a label generating 
a detectable signal. 
6. The method of claim 5, wherein the label comprises a
chemical, an enzymatic, a radioactive, a fluorescent, a 
luminescent, a chemiluminescent or a Fluorescence Reso­
nance Energy Transfer (FRET) label. 
7. The method of claim 1, wherein the detection of the
lipocalin-PDS/TTR complex is by enzyme-linked immu­
nosorbent assay (ELISA). 
8. The method of claim 1, wherein the detection of the
lipocalin-PDS/TTR complex is by enzyme-linked immu­
nosorbent assay (ELISA), and wherein the lipocalin-PDS/ 
TTR biomarker complex is a trimer consisting of one 
molecule of lipocalin-PDS and two molecules of TTR. 
9. The method of claim 2, wherein the rabbit anti-TTR
antibody further comprises a label generating a detectable 
signal. 
10. The method of claim 9, wherein the label comprises
a chemical, an enzymatic, a radioactive, a fluorescent, a 
luminescent, a chemiluminescent or a Fluorescence Reso­
nance Energy Transfer (FRET) label. 
11. The method of claim 1, and further comprising deter­
mining whether there is a lower concentration of lipocalin­
PDS/TTR complex in the smnple than in a normal control. 
* * * * *
